163 related articles for article (PubMed ID: 21412200)
1. The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome.
Dang D; Cunnington D; Swieca J
Clin Neuropharmacol; 2011; 34(2):66-70. PubMed ID: 21412200
[TBL] [Abstract][Full Text] [Related]
2. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists.
Tippmann-Peikert M; Park JG; Boeve BF; Shepard JW; Silber MH
Neurology; 2007 Jan; 68(4):301-3. PubMed ID: 17242339
[TBL] [Abstract][Full Text] [Related]
3. Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis.
Evans AH; Butzkueven H
Mov Disord; 2007 Mar; 22(4):590-1. PubMed ID: 17230484
[No Abstract] [Full Text] [Related]
4. [Impulse control disorders in Parkinson's disease: A cohort of 35 patients].
Carrière N; Kreisler A; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2012 Feb; 168(2):143-51. PubMed ID: 22129474
[TBL] [Abstract][Full Text] [Related]
5. [Dopamine dysregulation syndrome in Parkinson's disease and restless legs syndrome].
Bayard S; Cochen De Cock V; Dauvillers Y
Geriatr Psychol Neuropsychiatr Vieil; 2011 Jun; 9(2):227-35. PubMed ID: 21690031
[TBL] [Abstract][Full Text] [Related]
6. [Impulse control disorder induced by the use of dopamine agonists].
Weber WE; Nijssen PC
Ned Tijdschr Geneeskd; 2009 Jan; 153(3):80-1. PubMed ID: 19235343
[No Abstract] [Full Text] [Related]
7. Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome.
Dorfman BJ; Nirenberg MJ
Parkinsonism Relat Disord; 2013 Feb; 19(2):269-70. PubMed ID: 22749683
[No Abstract] [Full Text] [Related]
8. Major depression after withdrawing dopamine agonists in two patients with restless legs syndrome and impulse control disorders.
Launois C; Leu-Semenescu S; Brion A; Arnulf I
Sleep Med; 2013 Jul; 14(7):696. PubMed ID: 23714418
[No Abstract] [Full Text] [Related]
9. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
[TBL] [Abstract][Full Text] [Related]
10. Pathological gambling associated with dopamine agonist use in restless legs syndrome.
Quickfall J; Suchowersky O
Parkinsonism Relat Disord; 2007 Dec; 13(8):535-6. PubMed ID: 17270485
[TBL] [Abstract][Full Text] [Related]
11. Ropinirole in restless leg syndrome.
Ahmed I
Mo Med; 2002; 99(9):500-1. PubMed ID: 12462942
[TBL] [Abstract][Full Text] [Related]
12. Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome.
Bayard S; Langenier MC; Dauvilliers Y
Sleep; 2013 Oct; 36(10):1501-7. PubMed ID: 24082309
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood.
Montagna P; Hornyak M; Ulfberg J; Hong SB; Koester J; Crespi G; Albrecht S
Sleep Med; 2011 Jan; 12(1):34-40. PubMed ID: 20965780
[TBL] [Abstract][Full Text] [Related]
14. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample.
Allen RP; Ondo WG; Ball E; Calloway MO; Manjunath R; Higbie RL; Lee MR; Nisbet PA
Sleep Med; 2011 May; 12(5):431-9. PubMed ID: 21493132
[TBL] [Abstract][Full Text] [Related]
15. Long term follow-up of Parkinson's disease patients with impulse control disorders.
Sohtaoğlu M; Demiray DY; Kenangil G; Ozekmekçi S; Erginöz E
Parkinsonism Relat Disord; 2010 Jun; 16(5):334-7. PubMed ID: 20223696
[TBL] [Abstract][Full Text] [Related]
16. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome.
Silver N; Allen RP; Senerth J; Earley CJ
Sleep Med; 2011 May; 12(5):440-4. PubMed ID: 21239226
[TBL] [Abstract][Full Text] [Related]
17. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas.
Martinkova J; Trejbalova L; Sasikova M; Benetin J; Valkovic P
Clin Neuropharmacol; 2011; 34(5):179-81. PubMed ID: 21738024
[TBL] [Abstract][Full Text] [Related]
18. Impact of dopamine agonists on compulsive behaviors: a case series of pramipexole-induced pathological gambling.
Kolla BP; Mansukhani MP; Barraza R; Bostwick JM
Psychosomatics; 2010; 51(3):271-3. PubMed ID: 20484726
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
García-Borreguero D; Allen RP; Kohnen R; Högl B; Trenkwalder C; Oertel W; Hening WA; Paulus W; Rye D; Walters A; Winkelmann J; Earley CJ;
Sleep Med; 2007 Aug; 8(5):520-30. PubMed ID: 17544323
[TBL] [Abstract][Full Text] [Related]
20. Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease.
Potenza MN; Voon V; Weintraub D
Nat Clin Pract Neurol; 2007 Dec; 3(12):664-72. PubMed ID: 18046439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
